Opinion|Videos|November 26, 2024
Utilizing Antibiotics in Treatment of C Difficile
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- Antibiotics can disrupt gut microbiota, leading to potential recurrences of Clostridioides difficile infections (CDI).
- New therapies like fecal microbiota transplantation (FMT) and monoclonal antibodies aim to restore healthy gut flora and provide targeted immune support.
The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of antibiotics in the treatment of recurrent C difficile infections?
- Why was it necessary to develop new therapies beyond antibiotics?
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5